Prescription Drugs - Cuba

Cuba

The Prescription Drugs market in Cuba is anticipated to generate a revenue of US$2.35bn in 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2028) of 7.34%, leading to a market volume of US$3.12bn by 2028.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$358.90bn in 2024.
In terms of per capita figures, each person in Cuba is estimated to generate a revenue of US$210.40 in 2024.
Cuba's prescription drug market is heavily regulated, with limited access to foreign medications and a focus on locally produced generic drugs.

Key regions: France, Canada, United States, Australia, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Prescription Drugs (Pharmacies) market in Cuba is experiencing significant growth and development.

Customer preferences: Customers in Cuba have shown a strong preference for prescription drugs, which has contributed to the growth of the market. This preference can be attributed to several factors, including an aging population, increasing healthcare awareness, and the presence of chronic diseases. As the population ages, the demand for prescription drugs is expected to continue to rise. Additionally, with a greater emphasis on healthcare and wellness, consumers are becoming more proactive in seeking medical treatment and are more likely to rely on prescription drugs to manage their health conditions.

Trends in the market: One of the key trends in the Prescription Drugs (Pharmacies) market in Cuba is the increasing availability and accessibility of prescription drugs. This can be attributed to the government's efforts to improve healthcare infrastructure and expand access to healthcare services. The government has been investing in the development of pharmacies and healthcare facilities, making it easier for consumers to access prescription drugs. Furthermore, the government has implemented policies to ensure the affordability of prescription drugs, making them more accessible to a wider population. Another trend in the market is the growing demand for generic prescription drugs. Generic drugs are more affordable than their branded counterparts and offer similar therapeutic benefits. This has led to an increased demand for generic drugs among consumers, as they seek cost-effective alternatives. The government has also been promoting the use of generic drugs through various initiatives, further driving their demand in the market.

Local special circumstances: Cuba has a unique healthcare system, with a strong emphasis on preventive care and public health. This has contributed to the development of the Prescription Drugs (Pharmacies) market, as consumers are encouraged to seek medical treatment and manage their health conditions through prescription drugs. The government plays a central role in the healthcare system, ensuring the availability and affordability of prescription drugs for the population.

Underlying macroeconomic factors: The Prescription Drugs (Pharmacies) market in Cuba is influenced by several macroeconomic factors. One of the key factors is the country's economic growth and stability. As the economy continues to grow, consumers have more disposable income to spend on healthcare, including prescription drugs. This has contributed to the increasing demand for prescription drugs in the market. Another macroeconomic factor is the government's healthcare policies and regulations. The government has implemented policies to promote the use of prescription drugs and ensure their affordability. These policies have created a favorable environment for the growth of the Prescription Drugs (Pharmacies) market in Cuba. In conclusion, the Prescription Drugs (Pharmacies) market in Cuba is experiencing significant growth and development. This can be attributed to customer preferences for prescription drugs, increasing availability and accessibility of prescription drugs, the growing demand for generic drugs, the unique healthcare system in Cuba, and underlying macroeconomic factors such as economic growth and government policies. The market is expected to continue to grow as the population ages and healthcare awareness increases.

Methodology

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.